

States of America)

Kasper, Dennis L., Newton Centre, MA (Massachusetts), US
(United States of America)

Ausubel, Frederick M., Newton, MA (Massachusetts), US (United
States of America)

Madoff, Lawrence C., Boston, MA (Massachusetts), US (United
States of America)

ASSIGNEE(s): The Brigham and Women's Hospital, (A U.S. Company or
Corporation), Boston, MA (Massachusetts), US (United States of
America)

The General Hospital Corp , (A U.S. Company or Corporation),
Charlestown, MA (Massachusetts), US (United States of America)
[Assignee Code(s): 8822; 10301]

APPL. NO.: 8-463,288

FILED: June 05, 1995 (19950605)

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a division of application Ser. No. 08-363,311, filed
Dec. 22, 1994, U.S. Pat. No. 5,648,241, which is a continuation of
application Ser. No. 07-968,866, filed Nov. 2, 1992, now abandoned, which
is a continuation-in-part of U.S. application Ser. No. 07-408,036, filed
Sep. 15, 1989 now abandoned.

FULL TEXT: 3333 lines

ABSTRACT

A vaccine capable of protecting a recipient from infection caused by group
B Streptococcus. The vaccine provides polysaccharide-protein moieties and
contain (a) a group B Streptococcus polysaccharide conjugated to (b)) a
functional derivative of a group B Streptococcus C protein alpha %antigen%
that retains the ability to elicit protective antibodies against group B
Streptococcus. The vaccine may contain only one type of such
polysaccharide-protein unit or may contain a mixture of more than one type
of unit.

31/3,AB/9 (Item 9 from file: 654)

DIALOG(R) File 654:US PAT.FULL.

(c) FORMAT ONLY 2002 THE DIALOG CORP. All rts. reserv.

02668265

Utility

CONJUGATE VACCINE AGAINST GROUP B STREPTOCOCCUS

PATENT NO.: 5,648,241

ISSUED: July 15, 1997 (19970715)

INVENTOR(s): Michel, James L., Waban, MA (Massachusetts), US (United
States of America)

Kasper, Dennis L., Newton Centre, MA (Massachusetts), US
(United States of America)

Ausubel, Frederick M., Newton, MA (Massachusetts), US (United
States of America)

Madoff, Lawrence C., Boston, MA (Massachusetts), US (United
States of America)

ASSIGNEE(s): Brigham and Women's Hospital, (A U.S. Company or Corporation),
Boston, MA (Massachusetts), US (United States of America)

The General Hospital Corporation, (A U.S. Company or
Corporation), Charlestown, MA (Massachusetts), US (United
States of America)

[Assignee Code(s): 8822; 10301]

APPL. NO.: 8-363,311

FILED: December 22, 1994 (19941222)

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of application Ser. No. 07-968,866,

filed Nov. 2, 1992, abandoned, which is a continuation-in-part of application Ser. No. 07-408,036 filed Sep. 15, 1989, now abandoned.

This invention was made with government support; the government has certain rights in this invention.

FULL TEXT: 2849 lines

ABSTRACT

A purified DNA molecule is disclosed that comprises a DNA sequence encoding a Group B Streptococcus alpha %antigen% or antibody eliciting fragment. The alpha %antigen% sequence encodes several distinct domains including an N-terminal sequence that precedes the start of the alpha %antigen% repeating sequence, a C-terminal anchor sequence and a repeating unit motif. The ability to protect mice against a Streptococcus infection with antisera against cellular extracts containing the alpha %antigen% encoded by the DNA molecule was determined.

31/3,AB/10 (Item 1 from file: 349)
DIALOG(R) File 349:PCT FULLTEXT
(c) 2002 WIPO/Univentio. All rts. reserv.

00822902
PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE
%ANTIGEN% Nhha
PROTEINES COMPRENANT DES REGIONS CONSERVEES DE L'ANTIGENE DE SURFACE
NEISSERIA MENINGITIDIS (Nhha)

Patent Applicant/Assignee:

THE UNIVERSITY OF QUEENSLAND, St Lucia, Brisbane, Queensland 4072, AU, AU
(Residence), AU (Nationality)

Inventor(s):

PEAK Ian Richard Anselm, Unit 10, 81 Armadale Street, St Lucia, Brisbane,
Queensland 4067, AU,

JENNINGS Michael Paul, 20 Picasso Street, Carina, Brisbane, Queensland
4152, AU,

Legal Representative:

FISHER Adams Kelly (agent), Level 13, Amp Place, 10 Eacle Street,
Brisbane, Queensland 4000, AU,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200155182 A1 20010802 (WO 0155182)

Application: WO 2001AU69 20010125 (PCT/WO AU0100069)

Priority Application: US 2000177917 20000125

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ

DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ

LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG

SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 18627

English Abstract

Novel proteins that constitute modified forms of a Neisseria meningitidis surface %antigen% and encoding nucleic acids are provided. The modified surface proteins are characterized by having deletions of non-conserved amino acids, and thereby being capable of eliciting cross-protective immune responses against Neisseria meningitidis. The invention extends to the use of the modified surface antigens in diagnostics, in therapeutic and prophylactic vaccines and in the design and/or screening of medicaments. The modified surface antigens are particularly useful in vaccines which effectively immunize against a broader spectrum of N. meningitidis strains than would be expected from a corresponding

wild-type surface %antigen%.

French Abstract

L'invention porte sur de nouvelles proteines qui constituent des formes modifiees d'un antigene de surface *Neisseria meningitidis* et sur des acides nucleiques les codant. Les proteines de surface modifiees se caracterisent en ce qu'elles possedent des deletions d'acides amines non conservees et sont donc capables d'elicer des reponses immunes a protection croisee et dirigees contre *Neisseria meningitidis*. L'invention porte egalement sur l'utilisation des antigenes de surface modifies dans les diagnostics, dans les vaccins therapeutiques et prophylactiques et dans la conception et/ou le criblage de medicaments. Les antigenes de surface modifies sont notamment utiles dans des vaccins qui immunisent efficacement contre un plus large spectre de souches de *N. meningitidis* que ne le ferait un antigene de surface correspondant du type sauvage.

31/3,AB/11 (Item 2 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT
(c) 2002 WIPO/Univentio. All rts. reserv.

00743012

GENETICALLY MODIFIED PLANTS HAVING MODULATED BRASSINOSTEROID SIGNALING
PLANTES GENETIQUEMENT MODIFIEES PRESENTANT UNE SIGNALISATION
BRASSINOSTEROIDE MODULEE

Patent Applicant/Assignee:

THE SALK INSTITUTE FOR BIOLOGICAL STUDIES, 10010 North Torrey Pines Road,
La Jolla, CA 92037, US, US (Residence), US (Nationality), (For all
designated states except: US)

Patent Applicant/Inventor:

NEFF Michael M, 7125 Washington Avenue, St. Louis, MO 63130, US, US
(Residence), US (Nationality), (Designated only for: US)
CHORY Joanne, 727 Hoska Drive, Del Mar, CA 92014, US, US (Residence), US
(Nationality), (Designated only for: US)

Legal Representative:

HAILE Lisa A, Gray Cary Ware & Friedenrich LLP, Suite 1600, 4365
Executive Drive, San Diego, CA 92121-2189, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200055302 A2 20000921 (WO 0055302)
Application: WO 2000US6915 20000316 (PCT/WO US0006915)
Priority Application: US 99124570 19990316; US 99170931 19991214; US
99172832 19991220

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK

DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK
LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL
TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 31214

English Abstract

The present invention provides cytochrome P450s useful for producing genetically modified plants characterized as having the phenotypic trait of modulated brassinolide synthesis of signaling, for example, resulting in insect resistance, dwarfism and darker-green foliage compared with wild type plants. Such plants can be modified, for example, using "bas1", or functional homologues thereof, a polypeptide encoded by bas1 that modulates brassinolide synthesis and/or signaling in plants. The invention also provides methods for modulating ecdysteroid activity in a plant and for assaying brassinosteroid function in a plant. The latter method can be used to create a gain-of-function allelic series of plants characterized by increasing levels of overexpression of a cytochrome P450 to screen for brassinolide activity in plant species.

French Abstract

La presente invention concerne des cytochromes P450 utilises dans la production de plantes genetiquement modifiees, caracterises en ce qu'ils presentent le trait phenotypique de la synthese ou de la signalisation brassinolide modifiee, par exemple, entrainant la resistance aux insectes, le nanisme et un feuillage vert plus fonce par rapport aux plantes de type sauvage. En l'occurrence, On peut modifier ces plantes, par exemple, a l'aide de " bas1 ", ou d'homologues fonctionnels de celles-ci, ou d'un polypeptide code par bas1 qui module la synthese et/ou la signalisation brassinolide chez les plantes. Par ailleurs, cette invention concerne des procedes de modulation de l'activite ecdysteroides et d'analyse de fonction brassinosteroide dans une plante. On peut utiliser ce dernier procede pour mettre au point une serie allele de plantes fonction de gain, caracterisees par des niveaux accrues de surexpression d'un cytochrome P450, dans le but d'analyser l'activite brassinolide dans une espece de plantes.

31/3,AB/12 (Item 3 from file: 349)

DIALOG(R) File 349:PCT FULLTEXT

(c) 2002 WIPO/Univentio. All rts. reserv.

00571121

A RECOMBINANT VECTOR EXPRESSING MULTIPLE COSTIMULATORY MOLECULES AND USES THEREOF

VECTEUR RECOMBINE EXPRIMANT DES MOLECULES COSTIMULANTES MULTIPLES ET LEURS UTILISATIONS

Patent Applicant/Assignee:

THE GOVERNMENT OF THE UNITED STATES OF AMERICA represented by THE
SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES,
THERION BIOLOGICS CORPORATION,
SCHLOM Jeffrey,
HODGE James,
PANICALI Dennis,

Inventor(s):

SCHLOM Jeffrey,
HODGE James,
PANICALI Dennis,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200034494 A1 20000615 (WO 0034494)

Application: WO 99US26866 19991112 (PCT/WO US9926866)

Priority Application: US 98111582 19981209

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK

DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ
TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM
AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL
PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

Publication Language: English

Fulltext Word Count: 41813

English Abstract

The present invention is a recombinant vector encoding and expressing at least three or more costimulatory molecules. The recombinant vector may additionally contain a gene encoding one or more target antigens or immunological epitope thereof. The synergistic effect of these costimulatory molecules on the enhanced activation of T cells is demonstrated. The degree of T-cell activation using recombinant vectors containing genes encoding three costimulatory molecules was far greater than the sum of recombinant vector constructs containing one costimulatory molecule and greater than the use of two costimulatory molecules. Results employing the triple costimulatory vectors were most dramatic under conditions of either low levels of first signal or low stimulator to T-cell ratios. This phenomenon was observed with both isolated CD4+ and CD8+ T cells. The recombinant vectors of the present invention are useful as immunogenes and vaccines against cancer and pathogenic micro-organisms, and in providing host cells, including dendritic cells and splenocytes with enhanced %antigen%-presenting functions.

French Abstract

La presente invention est un vecteur recombiné codant et exprimant au moins trois molécules costimulantes ou davantage. Le vecteur recombiné peut également contenir un gène codant un ou plusieurs antigènes cibles ou leur épitope immunologique. L'effet synergique de ces molécules costimulantes sur l'activation renforcée des lymphocytes T est démontré. Le degré d'activation des lymphocytes T à l'aide de vecteurs recombinés contenant des gènes codant trois molécules costimulantes a été de loin supérieur à la somme des constructions de vecteurs recombinés contenant une molécule costimulante et supérieur à l'utilisation de deux molécules costimulantes. Les résultats employant les triples vecteurs costimulants se sont avérés spectaculaires dans des conditions de rapports entre soit de faibles niveaux d'un premier signal, soit un stimulateur faible et des lymphocytes T. On a observé ce phénomène avec des lymphocytes T isolés à la fois CD4+ et D8+. Les vecteurs recombinés de la présente invention sont utiles en tant qu'immunogènes et vaccins contre le cancer et des micro-organismes pathogènes, et pour obtenir des cellules hôtes, y compris des cellules dendritiques et des splénocytes présentant des fonctions renforcées de présentation d'antigène.

31/3,AB/13 (Item 4 from file: 349)
DIALOG(R) File 349:PCT FULLTEXT
(c) 2002 WIPO/Univentio. All rts. reserv.

00552286

STOMACH POLYPEPTIDE ZSIG28
POLYPEPTIDE STOMACHAL ZSIG28

Patent Applicant/Assignee:

ZYMOGENETICS INC,

Inventor(s):

SHEPPARD Paul O,

FOLEY Kevin P,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200015659 A2 20000323 (WO 0015659)

Application: WO 99US21023 19990914 (PCT/WO US9921023)

Priority Application: US 98154444 19980916

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE

ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT

LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT

UA UG UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD

RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF

CG CI CM GA GN GW ML MR NE SN TD TG

Publication Language: English

Fulltext Word Count: 31075

English Abstract

The present invention relates to polynucleotide and polypeptide molecules for zsig28, a novel member of the RPV.1 family of proteins. The polynucleotides encoding zsig28 can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.

French Abstract

La présente invention concerne des molécules de polynucleotides et de polypeptides de zsig28, nouveau membre de la famille RPV.1 des protéines. Les polynucleotides codant zsig28 peuvent servir à identifier une région du génome liée à des états pathologiques chez l'humain. La présente invention comprend également des procédés pour fabriquer la protéine, leur utilisation et des anticorps de ces molécules.

31/3,AB/14 (Item 5 from file: 349)
DIALOG(R) File 349:PCT FULLTEXT
(c) 2002 WIPO/Univentio. All rts. reserv.

00497988

AN OVER-EXPRESSING HOMOLOGOUS %ANTIGEN% VACCINE AND A METHOD OF MAKING THE

SAME

VACCIN CONTENANT UN ALLOANTIGENE SUREXPRIME ET SON PROCEDE DE PREPARATION

Patent Applicant/Assignee:

VIRGINIA TECH INTELLECTUAL PROPERTIES INC,
BOYLE Stephen M,
CRAVERO Silvio,
CORBEIL Lynette,
SCHURIG Gerhardt G,
SRIRNAGANATHAN Nammalwar,
VEMULAPALLI Ramesh,

Inventor(s):

BOYLE Stephen M,
CRAVERO Silvio,
CORBEIL Lynette,
SCHURIG Gerhardt G,
SRIRNAGANATHAN Nammalwar,
VEMULAPALLI Ramesh,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9929340 A1 19990617
Application: WO 97US23032 19971205 (PCT/WO US9723032)
Priority Application: WO 97US23032 19971205

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES

FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK
MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN
YU ZW GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK
ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN
TD TG

Publication Language: English

Fulltext Word Count: 5397

English Abstract

This invention relates to an over-expressing homologous %antigen% vaccine, a method of producing the same, and use of the vaccine for prophylaxis or treatment of vertebrates at risk of or suffering from disease caused by a pathogenic micro-organism. The vaccine is an attenuated or avirulent pathogenic micro-organism that %over%-expresses% at least one homologous %antigen% encoded by at least one gene derived from the pathogenic micro-organism, and may also express a heterologous %antigen%.

French Abstract

Cette invention concerne un vaccin contenant un alloantigene surexprime, un procede de preparation de ce vaccin et l'utilisation de ce dernier dans la prophylaxie ou le traitement de vertebres qui presentent le risque de souffrir d'une maladie provoquee par un micro-organisme pathogene ou qui souffrent deja d'une telle maladie. Le vaccin est un micro-organisme pathogene attenué ou avirulent qui surexprime au moins un alloantigene code par au moins un gene provenant du micro-organisme pathogene, et qui peut egalement exprimer un antigene heterologue.

31/3,AB/15 (Item 6 from file: 349)

DIALOG(R) File 349:PCT FULLTEXT

(c) 2002 WIPO/Univentio. All rts. reserv.

00412003

THERAPEUTIC MULTISPECIFIC COMPOUNDS COMPRISED OF ANTI-FC'alpha' RECEPTOR ANTIBODIES

COMPOSES THERAPEUTIQUES A SPECIFICITE MULTIPLE CONSISTANT EN ANTICORPS ANTI-RECEPTEURS DU FC'alpha'

Patent Applicant/Assignee:

MEDAREX INC,
DEO Yashwant M,
GRAZIANO Robert,
KELER Tibor,

Inventor(s):

DEO Yashwant M,
GRAZIANO Robert,
KELER Tibor,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9802463 A1 19980122

Application: WO 97US12013 19970710 (PCT/WO US9712013)

Priority Application: US 96678194 19960711

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CZ DE DK EE ES FI

GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW

MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI

FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

Publication Language: English

Fulltext Word Count: 27643

English Abstract

Multispecific compounds comprising at least one binding determinant which binds to the Fc γ -receptor on an effector cell. The other binding determinant(s) binds(s) to one or more antigens on a target cell, e.g., the Neu/Her-2 proto-oncogene product or the epidermal growth factor receptor on cancer cells, or to Candida antigens on infected cells. Examples are biospecific and trispecific antibodies. Therapeutic use of said multispecific compounds for treatment of cancers or pathogen infections.

French Abstract

L'invention porte sur des composés thérapeutiques à spécificité multiple comprenant au moins un déterminant de liaison se fixant aux récepteurs du FC' α ' d'une cellule effectrice. Les autres déterminants de liaison se fixent à un ou plusieurs antigènes d'une cellule cible, par exemple produit proto-oncogénique Neu/Her-2, récepteur du facteur de croissance épidermique de cellules cancéreuses ou aux antigènes du Candida de cellules infectées. Les exemples en sont des anticorps biospécifiques ou trispécifiques. L'invention porte également sur l'utilisation thérapeutique desdits composés multispécifiques pour le traitement du cancer et des infections dues à des pathogènes.

31/3,AB/16 (Item 7 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2002 WIPO/Univentio. All rts. reserv.

00262149

CONJUGATE VACCINE AGAINST GROUP B STREPTOCOCCUS

VACCIN CONJUGUE CONTRE DES STREPTOCOQUES DU GROUPE B

Patent Applicant/Assignee:

THE GENERAL HOSPITAL CORPORATION,

BRIGHAM AND WOMEN'S HOSPITAL,

Inventor(s):

MICHEL James L,

KASPER Dennis L,

AUSUBEL Frederick M,

MADOFF Lawrence C,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9410317 A2 19940511

Application: WO 93US10506 19931102 (PCT/WO US9310506)

Priority Application: US 92968866 19921102

Designated States: AU CA FI HU JP KR NO NZ PL RU AT BE CH DE DK ES FR GB GR

IE IT LU MC NL PT SE

Publication Language: English

Fulltext Word Count: 28284

English Abstract

A vaccine capable of protecting a recipient from infection caused by group B Streptococcus. The vaccine provides polysaccharide-protein moieties and contain (a) a group B Streptococcus polysaccharide conjugated to (b) a functional derivative of a group B Streptococcus C protein α antigen that retains the ability to elicit protective antibodies against group B Streptococcus. The vaccine may contain only one type of such polysaccharide-protein unit or may contain a mixture of more than one type of unit.

French Abstract

On decrit un vaccin qui protege des infections dues a des streptocoques du groupe B. Ce vaccin presente des fractions polysaccharides-proteines et contient: a) un polysaccharide de streptocoque du groupe B conjugue a b) un derive fonctionnel d'un antigene alpha de proteine C d'un streptocoque du groupe B qui garde la capacite d'induire des anticorps protecteurs contre des streptocoques du groupe B. Ce vaccin peut ne contenir qu'un type d'une telle unite polysaccharide-proteine ou un melange de plusieurs types de ces unites.

31/3,AB/17 (Item 8 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT
(c) 2002 WIPO/Univentio. All rts. reserv.

00186706

CONJUGATE VACCINE FOR GROUP B STREPTOCOCCUS
VACCIN CONJUGUE POUR STREPTOCOQUE DU GROUBE B
Patent Applicant/Assignee:

THE GENERAL HOSPITAL CORPORATION,
BRIGHAM AND WOMEN'S HOSPITAL,

Inventor(s):

MICHEL James L,
KASPER Dennis L,
AUSUBEL Frederick M,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9104049 A1 19910404

Application: WO 90US5251 19900914 (PCT/WO US9005251)

Priority Application: US 8936 19890915

Designated States: AT AU BE CA CH DE DK ES FI FR GB HU IT JP KR LU NL NO SE
SU

Publication Language: English

Fulltext Word Count: 17268

English Abstract

A vaccine capable of protecting a recipient from infection caused by group B Streptococcus. The vaccine is formed by conjugating (a) a polysaccharide conjugated to (b) a protein; wherein both the polysaccharide and the protein are characteristic molecules of the group B Streptococcus.

French Abstract

L'invention concerne un vaccin pouvant proteger un receveur contre des infections provoquees par les streptocoques du groupe B. Le vaccin est forme par conjugaison (a) d'un polysaccharide conjugue avec (b) une proteine. Tant le polysaccharide que la proteine sont des molecules caracteristiques du streptocoque du groupe B.

31/3,AB/18 (Item 1 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS
(c) 2002 European Patent Office. All rts. reserv.

00452597

CONJUGATE VACCINE FOR GROUP B STREPTOCOCCUS
KONJUGATIMPFSTOFF FUR GRUPPE B-STREPTOCOCCUS
VACCIN CONJUGUE POUR STREPTOCOQUE DU GROUBE B
PATENT ASSIGNEE:

THE GENERAL HOSPITAL CORPORATION, (370400), 55 Fruit Street, Boston, MA
02114, (US), (applicant designated states:

AT;BE;CH;DE;DK;ES;FR;GB;IT;LI;LU;NL;SE)

BRIGHAM AND WOMEN'S HOSPITAL, (351461), 75 Francis Street, Boston,
Massachusetts 02115, (US), (applicant designated states:

AT;BE;CH;DE;DK;ES;FR;GB;IT;LI;LU;NL;SE)

INVENTOR:

MICHEL, James, L., 196 Winslow Road, Waban, MA 02168, (US)

KASPER, Dennis, L., 544 Ward Street, Newton Centre, MA 02159, (US)

AUSUBEL, Frederick, M., 271 Lake Avenue, Newton, MA 02161, (US)

LEGAL REPRESENTATIVE:

Aulmich, Gerhard, Dr. et al (9141), Hoechst AG Patent- und
Lizenzabteilung Gebaude K 801, 65926 Frankfurt am Main, (DE)
PATENT (CC, No, Kind, Date): EP 491865 A1 920701 (Basic)

EP 491865 A1 930505
EP 491865 B1 961211
WO 9104049 910404

APPLICATION (CC, No, Date): EP 90915038 900914; WO 90US5251 900914

PRIORITY (CC, No, Date): US 408036 890915

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; IT; LI; LU; NL; SE

INTERNATIONAL PATENT CLASS: A61K-039/09; C12N-015/31; C07K-016/46;

NOTE:

No A-document published by EPO

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPAB96	366
CLAIMS B	(German)	EPAB96	382
CLAIMS B	(French)	EPAB96	363
SPEC B	(English)	EPAB96	14514

Total word count - document A 0

Total word count - document B 15625

Total word count - documents A + B 15625

31/3,AB/19 (Item 1 from file: 149)

DIALOG(R)File 149:TGG Health&Wellness DB(SM)

(c) 2002 The Gale Group. All rts. reserv.

01619731 SUPPLIER NUMBER: 18306605 (USE FORMAT 7 OR 9 FOR FULL TEXT)

Cystic fibrosis in adults: from researcher to practitioner.

Marelich, Gregory P.; Cross, Carroll E.

The Western Journal of Medicine, v164, n4, p321(14)

April,

1996

PUBLICATION FORMAT: Magazine/Journal ISSN: 0093-0415 LANGUAGE: English

RECORD TYPE: Fulltext; Abstract TARGET AUDIENCE: Professional

WORD COUNT: 13175 LINE COUNT: 01133

AUTHOR ABSTRACT: The Cystic Fibrosis Foundation currently tracks about 20,000 Americans with cystic fibrosis, an autosomal recessive genetic disease that leads to multisystem complications. With the institution of better therapeutic regimens over the past 2 decades, more patients with this disease are surviving to adulthood. Within the past decade, both clinical and basic science research in the field of cystic fibrosis has progressed at a rapid rate. The intent of this review is to introduce readers to the molecular, cellular, and systemic disorders of this disease. We discuss treatment strategies involving antibiotics, nutrition, immune-response mediators, chest physiotherapy, and sputum-active agents with respect to the airway dysfunction of cystic fibrosis. Other common complications, recent developments, transplantation, and gene therapy are also reviewed.

31/3,AB/20 (Item 1 from file: 340)

DIALOG(R)File 340:CLAIMS(R)/US Patent

(c) 2002 IFI/CLAIMS(R). All rts. reserv.

Dialog Acc No: 3419951 IFI Acc No: 0038796

Document Type: C

OVER-EXPRESSING HOMOLOGOUS %ANTIGEN% VACCINE AND A METHOD OF MAKING THE SAME; VACCINE FOR IMMUNIZATION, PROPHYLAXIS OR TREATMENT OF A VERTEBRATE AT RISK OF OR SUFFERING FROM BRUCELLOSIS, WHEREIN SAID VACCINE COMPRISES AN ATTENUATED OR AVIRULENT STRAIN OF AN OTHERWISE %PATHOGENIC% %BACTERIA% OF THE GENUS BRUCELLA

Inventors: Boyle Stephen M (US); Corbeil Lynette (US); Cravero Silvio (AR); Schurig Gerhardt (US); Sriranganathan Nammalwar (US); Vemulapalli Ramesh (US)

Assignee: California, University of Regents; Virginia Tech Intellectual Properties Inc Assignee Code: 13234 21457

Publication (No,Date), Applic (No,Date)

US 6149920 20001121 US 9891521 19980619

Publication Kind: A

Calculated Expiration: 20171205

PCT Pub(No,Date),Applic(No,Date): WO 9929340 19990617 WO 97US23032
19971205

Section 371: 19980619

Section 102(e):19980619

Priority Applic(No,Date): US 9891521 19980619

Abstract:

This invention relates to an over-expressing homologous %antigen% vaccine, a method of producing the same, and use of the vaccine for prophylaxis or treatment of vertebrates at risk of or suffering from disease caused by a pathogenic micro-organism. The vaccine is an attenuated or avirulent pathogenic micro-organism that %over%-expresses% at least one homologous %antigen% encoded by at least one gene derived from the pathogenic micro-organism, and may also express a heterologous %antigen%.

?

S27 63239 PATHOGENIC (1W) BACTERIA
S28 2720 S27 AND ANTIGEN
S29 3707 S28 AND OVER-EXPRESSES OR OVEREXPRESSES OR OVER (1W) EXPRE-
SSES
S30 20 S29 AND S28
S31 20 RD (unique items)
? t s31/3,ab/1-20

>>>No matching display code(s) found in file(s): 135, 180, 342, 624, 765

31/3,AB/1 (Item 1 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) FORMAT ONLY 2002 THE DIALOG CORP. All rts. reserv.

03432500

Utility
IMMUNOGENIC COMPOSITION FOR GROUP B STREPTOCOCCUS

PATENT NO.: 6,342,223
ISSUED: January 29, 2002 (20020129)
INVENTOR(s): Michel, James L., Waban, MA (Massachusetts), US (United States of America)
Kasper, Dennis L., Newton Centre, MA (Massachusetts), US (United States of America)
Ausubel, Frederick M., Newton, MA (Massachusetts), US (United States of America)
Madoff, Lawrence C., Boston, MA (Massachusetts), US (United States of America)
ASSIGNEE(s): The General Hospital Corporation & Brigham and Women's Hospital, (A U.S. Company or Corporation), Boston, MA (Massachusetts), US (United States of America)
APPL. NO.: 9-346,290
FILED: July 20, 1999 (19990720)

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 08-469,014 filed Jun. 5, 1995 (U.S. Pat. No. 5,968,521) issued Jan. 19, 1999, which is a division of U.S. application Ser. No. 08-363,311 filed Dec. 22, 1994 (U.S. Pat. No. 5,648,241) issued Jul. 15, 1997 which is a continuation of application Ser. No. 07-968,866 filed Nov. 2, 1992, now abandoned, which is a continuation-in-part of U.S. application Ser. No. 07-408,036, filed Sep. 15, 1989, now abandoned.

This invention was made with government support; the government has certain rights in this invention.

FULL TEXT: 2449 lines

ABSTRACT

A vaccine capable of protecting a recipient from infection caused by group B Streptococcus. The vaccine provides polysaccharide-protein moieties and contain (a) a group B Streptococcus polysaccharide conjugated to (b) a functional derivative of a group B Streptococcus C protein alpha antigen that retains the ability to elicit protective antibodies against group B Streptococcus. The vaccine may contain only one type of such polysaccharide-protein unit or may contain a mixture of more than one type of unit.

31/3,AB/2 (Item 2 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) FORMAT ONLY 2002 THE DIALOG CORP. All rts. reserv.

03220360

Utility

OVER-EXPRESSING HOMOLOGOUS %ANTIGEN% VACCINE AND A METHOD OF MAKING THE SAME

[Vaccine for immunization, prophylaxis or treatment of a vertebrate at risk of or suffering from Brucellosis, wherein said vaccine comprises an attenuated or avirulent strain of an otherwise %pathogenic% %bacteria% of the genus Brucella]

PATENT NO.: 6,149,920

ISSUED: November 21, 2000 (20001121)

INVENTOR(s): Boyle, Stephen M., Blacksburg, VA (Virginia), US (United States of America)

Cravero, Silvio, Republica, AR (Argentina)

Corbeil, Lynette, San Diego, CA (California), US (United States of America)

Schurig, Gerhard, Blacksburg, VA (Virginia), US (United States of America)

Srirnaganathan, Nammalwar, Blacksburg, VA (Virginia), US (United States of America)

Vemulapalli, Ramesh, Blacksburg, VA (Virginia), US (United States of America)

ASSIGNEE(s): The Regents of the University of California, (A U.S. Company or Corporation), La Jolla, CA (California), US (United States of America)

Virginia Tech Intellectual Properties, Inc, (A U.S. Company or Corporation), Blacksburg, VA (Virginia), US (United States of America)

[Assignee Code(s): 13234; 21457]

EXTRA INFO: Assignment transaction [Reassigned], recorded November 28, 2000 (20001128)

Assignment transaction [Reassigned], recorded November 30, 2000 (20001130)

APPL. NO.: 9-91,521

FILED: June 19, 1998 (19980619)

PCT: PCT-US97-23032 (WO 97US23032)

Section 371 Date: June 19, 1998 (19980619)

Section 102(e) Date: June 19, 1998 (19980619)

Filing Date: December 05, 1997 (19971205)

Publication Number: WO99-29340 (WO 9929340)

Publication Date: June 17, 1999 (19990617)

The invention described herein was made under a grant from the United States Department of Agriculture. Therefore, the U.S. government may have certain rights in this invention.

FULL TEXT: 520 lines

ABSTRACT

This invention relates to an over-expressing homologous %antigen% vaccine, a method of producing the same, and use of the vaccine for prophylaxis or treatment of vertebrates at risk of or suffering from disease caused by a pathogenic micro-organism. The vaccine is an attenuated or avirulent pathogenic micro-organism that %over%-expresses% at least one homologous %antigen% encoded by at least one gene derived from the pathogenic micro-organism, and may also express a heterologous %antigen%.

31/3,AB/3 (Item 3 from file: 654)

DIALOG(R) File 654:US PAT.FULL.

(c) FORMAT ONLY 2002 THE DIALOG CORP. All rts. reserv.

03019580

Utility

CONJUGATE VACCINE FOR GROUP B STREPTOCOCCUS

[Capsular polysaccharide to elicit antibodies and protein antigens]

PATENT NO.: 5,968,521

ISSUED: October 19, 1999 (19991019)

INVENTOR(s): Michel, James L., Waban, MA (Massachusetts), US (United States of America)
Kasper, Dennis L., Newton Centre, MA (Massachusetts), US (United States of America)
Ausubel, Frederick M., Newton, MA (Massachusetts), US (United States of America)
Madoff, Lawrence C., Boston, MA (Massachusetts), US (United States of America)
ASSIGNEE(s): Brigham and Women's Hospital, (A U.S. Company or Corporation), Boston, MA (Massachusetts), US (United States of America)
The General Hospital Corporation, (A U.S. Company or Corporation), Boston, MA (Massachusetts), US (United States of America)
[Assignee Code(s): 8822; 10301]
APPL. NO.: 8-469,014
FILED: June 05, 1995 (19950605)

CROSS REFERENCE TO RELATED APPLICATIONS:

This application is a division of application Ser. No. 08-363,311, filed Dec. 22, 1994, U.S. Pat. No. 5,648,241 which is a continuation of application Ser. No. 07-968,866, filed Nov. 2, 1992, now abandoned which is a continuation-in-part of U.S. application Ser. No. 07-408,036, filed Sep. 15, 1989, now abandoned.

This invention was made with government support; the government has certain rights in this invention.

FULL TEXT: 3358 lines

ABSTRACT

A vaccine capable of protecting a recipient from infection caused by group B Streptococcus. The vaccine provides polysaccharide-protein moieties and contain (a) a group B Streptococcus polysaccharide conjugated to (b) a functional derivative of a group B Streptococcus C protein alpha antigen that retains the ability to elicit protective antibodies against group B Streptococcus. The vaccine may contain only one type of such polysaccharide-protein unit or may contain a mixture of more than one type of unit.

31/3,AB/4 (Item 4 from file: 654)
DIALOG(R) File 654:US PAT.FULL.
(c) FORMAT ONLY 2002 THE DIALOG CORP. All rts. reserv.

02954542

Utility
CONJUGATE VACCINE FOR GROUP B STREPTOCOCCUS
[Polysaccharide-protein complex]

PATENT NO.: 5,908,629
ISSUED: June 01, 1999 (19990601)
INVENTOR(s): Michel, James L., Waban, MA (Massachusetts), US (United States of America)
Kasper, Dennis L., Newton Centre, MA (Massachusetts), US (United States of America)
Ausubel, Frederick M., Newton, MA (Massachusetts), US (United States of America)
Madoff, Lawrence C., Boston, MA (Massachusetts), US (United States of America)
ASSIGNEE(s): Brigham and Women's Hospital, (A U.S. Company or Corporation), Boston, MA (Massachusetts), US (United States of America)
The General Hospital Corporation, (A U.S. Company or Corporation), Boston, MA (Massachusetts), US (United States of America)
[Assignee Code(s): 8822; 10301]

APPL. NO.: 8-467,147
FILED: June 06, 1995 (19950606)

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a division of application Ser. No. 08-363,311, filed Dec. 22, 1994, now U.S. Pat. No. 5,648,241 which is a continuation of application Ser. No. 07-968,866, filed Nov. 2, 1992, now abandoned, which is a continuation-in-part of U.S. application Ser. No. 07-408,036, filed Sep. 15, 1989, now abandoned.

This invention was made with government support; the government has certain rights in this invention.

FULL TEXT: 3341 lines

ABSTRACT

A vaccine capable of protecting a recipient from infection caused by group B Streptococcus. The vaccine provides polysaccharide-protein moieties and contain (a) a group B Streptococcus polysaccharide conjugated to (b) a functional derivative of a group B Streptococcus C protein alpha antigen that retains the ability to elicit protective antibodies against group B Streptococcus. The vaccine may contain only one type of such polysaccharide-protein unit or may contain a mixture of more than one type of unit.

31/3,AB/5 (Item 5 from file: 654)
DIALOG(R) File 654:US PAT.FULL.
(c) FORMAT ONLY 2002 THE DIALOG CORP. All rts. reserv.

02898169

Utility
CONJUGATE VACCINE FOR GROUP B STREPTOCOCCUS
[Polysaccharide-protein]

PATENT NO.: 5,858,362
ISSUED: January 12, 1999 (19990112)
INVENTOR(s): Michel, James L., Waban, MA (Massachusetts), US (United States of America)
Kasper, Dennis L., Newton Centre, MA (Massachusetts), US (United States of America)
Ausubel, Frederick M., Newton, MA (Massachusetts), US (United States of America)
Madoff, Lawrence C., Boston, MA (Massachusetts), US (United States of America)
ASSIGNEE(s): Brigham and Women's Hospital, (A U.S. Company or Corporation), Boston, MA (Massachusetts), US (United States of America)
The General Hospital Corporation, (A U.S. Company or Corporation), Boston, MA (Massachusetts), US (United States of America)
[Assignee Code(s): 8822; 10301]
APPL. NO.: 8-466,210
FILED: June 06, 1995 (19950606)

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a division of application Ser. No. 08-363,311, filed Dec. 22, 1994, U.S. Pat. No. 5,648,241, which is a continuation of application Ser. No. 07-968,866, filed Nov. 2, 1992, now abandoned, which is a continuation-in-part of U.S. application Ser. No. 07-408,036, filed Sep. 15, 1989 now abandoned.

This invention was made with government support; the government has certain rights in this invention.

FULL TEXT: 3292 lines

ABSTRACT

A vaccine capable of protecting a recipient from infection caused by group B Streptococcus. The vaccine provides polysaccharide-protein moieties and contain (a) a group B Streptococcus polysaccharide conjugated to (b) a functional derivative of a group B Streptococcus C protein alpha antigen that retains the ability to elicit protective antibodies against group B Streptococcus. The vaccine may contain only one type of such polysaccharide-protein unit or may contain a mixture of more than one type of unit.

31/3,AB/6 (Item 6 from file: 654)
DIALOG(R) File 654:US PAT.FULL.
(c) FORMAT ONLY 2002 THE DIALOG CORP. All rts. reserv.

02885251

Utility
CONJUGATE VACCINE FOR GROUP B STREPTOCOCCUS

PATENT NO.: 5,847,081
ISSUED: December 08, 1998 (19981208)
INVENTOR(s): Michel, James L., Waban, MA (Massachusetts), US (United States of America)
Kasper, Dennis L., Newton Centre, MA (Massachusetts), US (United States of America)
Ausubel, Frederick M., Newton, MA (Massachusetts), US (United States of America)
Madoff, Lawrence C., Boston, MA (Massachusetts), US (United States of America)
ASSIGNEE(s): The Brigham and Women's Hospital, (A U.S. Company or Corporation), Boston, MA (Massachusetts), US (United States of America)
The General Hospital Corp, (A U.S. Company or Corporation), Charlestown, MA (Massachusetts), US (United States of America)
[Assignee Code(s): 8822; 10301]
APPL. NO.: 8-462,679
FILED: June 05, 1995 (19950605)

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a division of application Ser. No. 08-363,311, filed Dec. 22, 1994, U.S. Pat. No. 5,648,241, which is a continuation of application Ser. No. 07-968,866, filed Nov. 2, 1992, now abandoned, which is a continuation-in-part of U.S. application Ser. No. 07-408,036, filed Sep. 15, 1989 now abandoned.

This invention was made with government support; the government has certain rights in this invention.

FULL TEXT: 3179 lines

ABSTRACT

A vaccine capable of protecting a recipient from infection caused by group B Streptococcus. The vaccine provides polysaccharide-protein moieties and contain (a) a group B Streptococcus polysaccharide conjugated to (b) a functional derivative of a group B Streptococcus C protein alpha antigen that retains the ability to elicit protective antibodies against group B Streptococcus. The vaccine may contain only one type of such polysaccharide-protein unit or may contain a mixture of more than one type of unit.

31/3,AB/7 (Item 7 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) FORMAT ONLY 2002 THE DIALOG CORP. All rts. reserv.

02881335

Utility
CONJUGATE VACCINE FOR GROUP B STREPTOCOCCUS

PATENT NO.: 5,843,444
ISSUED: December 01, 1998 (19981201)
INVENTOR(s): Michel, James L., Waban, MA (Massachusetts), US (United States of America)
Kasper, Dennis L., Newton, MA (Massachusetts), US (United States of America)
Ausubel, Frederick M., Newton, MA (Massachusetts), US (United States of America)
Madoff, Lawrence C., Boston, MA (Massachusetts), US (United States of America)
ASSIGNEE(s): Brigham and Women's Hospital, (A U.S. Company or Corporation), Boston, MA (Massachusetts), US (United States of America)
The General Hospital Corporation, (A U.S. Company or Corporation), Boston, MA (Massachusetts), US (United States of America)
[Assignee Code(s): 8822; 10301]
APPL. NO.: 8-470,445
FILED: June 06, 1995 (19950606)

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a division of application Ser. No. 08-363,311, filed Dec. 22, 1994, U.S. Pat. No. 5,648,241 which is a continuation of application Ser. No. 07-968,866, filed Nov. 2, 1992, now abandoned, which is a continuation-in-part of U.S. application Ser. No. 07-408,036, filed Sep. 15, 1989, now abandoned.

This invention was made with government support; the government has certain rights in this invention.

FULL TEXT: 3291 lines

ABSTRACT

A vaccine capable of protecting a recipient from infection caused by group B Streptococcus. The vaccine provides polysaccharide-protein moieties and contain (a) a group B Streptococcus polysaccharide conjugated to (b) a functional derivative of a group B Streptococcus C protein alpha %antigen% that retains the ability to elicit protective antibodies against group B Streptococcus. The vaccine may contain only one type of such polysaccharide-protein unit or may contain a mixture of more than one type of unit.

31/3,AB/8 (Item 8 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) FORMAT ONLY 2002 THE DIALOG CORP. All rts. reserv.

02856712

Utility
CONJUGATE VACCINE FOR GROUP B STREPTOCOCCUS
[Comprises a capsular polysaccharide that elicits antibodies to group B Streptococcus conjugated to a C protein alpha %antigen% or beta %antigen% of said group B Streptococcus]

PATENT NO.: 5,820,860
ISSUED: October 13, 1998 (19981013)
INVENTOR(s): Michel, James L., Waban, MA (Massachusetts), US (United

States of America)

Kasper, Dennis L., Newton Centre, MA (Massachusetts), US
(United States of America)

Ausubel, Frederick M., Newton, MA (Massachusetts), US (United
States of America)

Madoff, Lawrence C., Boston, MA (Massachusetts), US (United
States of America)

ASSIGNEE(s): The Brigham and Women's Hospital, (A U.S. Company or
Corporation), Boston, MA (Massachusetts), US (United States of
America)

The General Hospital Corp , (A U.S. Company or Corporation),
Charlestown, MA (Massachusetts), US (United States of America)
[Assignee Code(s): 8822; 10301]

APPL. NO.: 8-463,288

FILED: June 05, 1995 (19950605)

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a division of application Ser. No. 08-363,311, filed
Dec. 22, 1994, U.S. Pat. No. 5,648,241, which is a continuation of
application Ser. No. 07-968,866, filed Nov. 2, 1992, now abandoned, which
is a continuation-in-part of U.S. application Ser. No. 07-408,036, filed
Sep. 15, 1989 now abandoned.

FULL TEXT: 3333 lines

ABSTRACT

A vaccine capable of protecting a recipient from infection caused by group
B Streptococcus. The vaccine provides polysaccharide-protein moieties and
contain (a) a group B Streptococcus polysaccharide conjugated to (b)) a
functional derivative of a group B Streptococcus C protein alpha %antigen%
that retains the ability to elicit protective antibodies against group B
Streptococcus. The vaccine may contain only one type of such
polysaccharide-protein unit or may contain a mixture of more than one type
of unit.

31/3,AB/9 (Item 9 from file: 654)

DIALOG(R) File 654:US PAT.FULL.

(c) FORMAT ONLY 2002 THE DIALOG CORP. All rts. reserv.

02668265

Utility

CONJUGATE VACCINE AGAINST GROUP B STREPTOCOCCUS

PATENT NO.: 5,648,241

ISSUED: July 15, 1997 (19970715)

INVENTOR(s): Michel, James L., Waban, MA (Massachusetts), US (United
States of America)

Kasper, Dennis L., Newton Centre, MA (Massachusetts), US
(United States of America)

Ausubel, Frederick M., Newton, MA (Massachusetts), US (United
States of America)

Madoff, Lawrence C., Boston, MA (Massachusetts), US (United
States of America)

ASSIGNEE(s): Brigham and Women's Hospital, (A U.S. Company or Corporation),
Boston, MA (Massachusetts), US (United States of America)
The General Hospital Corporation, (A U.S. Company or
Corporation), Charlestown, MA (Massachusetts), US (United
States of America)

[Assignee Code(s): 8822; 10301]

APPL. NO.: 8-363,311

FILED: December 22, 1994 (19941222)

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of application Ser. No. 07-968,866,

filed Nov. 2, 1992, abandoned, which is a continuation-in-part of application Ser. No. 07-408,036 filed Sep. 15, 1989, now abandoned.

This invention was made with government support; the government has certain rights in this invention.

FULL TEXT: 2849 lines

ABSTRACT

A purified DNA molecule is disclosed that comprises a DNA sequence encoding a Group B Streptococcus alpha antigen or antibody eliciting fragment. The alpha antigen sequence encodes several distinct domains including an N-terminal sequence that precedes the start of the alpha antigen repeating sequence, a C-terminal anchor sequence and a repeating unit motif. The ability to protect mice against a Streptococcus infection with antisera against cellular extracts containing the alpha antigen encoded by the DNA molecule was determined.

31/3,AB/10 (Item 1 from file: 349)
DIALOG(R) File 349:PCT FULLTEXT
(c) 2002 WIPO/Univentio. All rts. reserv.

00822902
PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE
%ANTIGEN% Nhha
PROTEINES COMPRENANT DES REGIONS CONSERVEES DE L'ANTIGENE DE SURFACE
NEISSERIA MENINGITIDIS (Nhha)

Patent Applicant/Assignee:

THE UNIVERSITY OF QUEENSLAND, St Lucia, Brisbane, Queensland 4072, AU, AU
(Residence), AU (Nationality)

Inventor(s):

PEAK Ian Richard Anselm, Unit 10, 81 Armadale Street, St Lucia, Brisbane,
Queensland 4067, AU,
JENNINGS Michael Paul, 20 Picasso Street, Carina, Brisbane, Queensland
4152, AU,

Legal Representative:

FISHER Adams Kelly (agent), Level 13, Amp Place, 10 Eacle Street,
Brisbane, Queensland 4000, AU,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200155182 A1 20010802 (WO 0155182)
Application: WO 2001AU69 20010125 (PCT/WO AU0100069)
Priority Application: US 2000177917 20000125

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ

DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ
LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG
SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 18627

English Abstract

Novel proteins that constitute modified forms of a Neisseria meningitidis surface antigen and encoding nucleic acids are provided. The modified surface proteins are characterized by having deletions of non-conserved amino acids, and thereby being capable of eliciting cross-protective immune responses against Neisseria meningitidis. The invention extends to the use of the modified surface antigens in diagnostics, in therapeutic and prophylactic vaccines and in the design and/or screening of medicaments. The modified surface antigens are particularly useful in vaccines which effectively immunize against a broader spectrum of N. meningitidis strains than would be expected from a corresponding

wild-type surface %antigen%.

French Abstract

L'invention porte sur de nouvelles proteines qui constituent des formes modifiees d'un antigene de surface <i>Neisseria meningitidis</i> et sur des acides nucleiques les codant. Les proteines de surface modifiees se caracterisent en ce qu'elles possedent des deletions d'acides amines non conserves et sont donc capables d'elicer des reponses immunes a protection croisee et dirigees contre <i>Neisseria meningitidis</i>. L'invention porte egalement sur l'utilisation des antigenes de surface modifies dans les diagnostics, dans les vaccins therapeutiques et prophylactiques et dans la conception et/ou le criblage de medicaments. Les antigenes de surface modifies sont notamment utiles dans des vaccins qui immunisent efficacement contre un plus large spectre de souches de <i>N. meningitidis</i> que ne le ferait un antigene de surface correspondant du type sauvage.

31/3,AB/11 (Item 2 from file: 349)
DIALOG(R) File 349:PCT FULLTEXT
(c) 2002 WIPO/Univentio. All rts. reserv.

00743012

GENETICALLY MODIFIED PLANTS HAVING MODULATED BRASSINOSTEROID SIGNALING
PLANTES GENETIQUEMENT MODIFIEES PRESENTANT UNE SIGNALISATION
BRASSINOSTEROIDE MODULEE

Patent Applicant/Assignee:

THE SALK INSTITUTE FOR BIOLOGICAL STUDIES, 10010 North Torrey Pines Road,
La Jolla, CA 92037, US, US (Residence), US (Nationality), (For all
designated states except: US)

Patent Applicant/Inventor:

NEFF Michael M, 7125 Washington Avenue, St. Louis, MO 63130, US, US
(Residence), US (Nationality), (Designated only for: US)
CHORY Joanne, 727 Hoska Drive, Del Mar, CA 92014, US, US (Residence), US
(Nationality), (Designated only for: US)

Legal Representative:

HAILE Lisa A, Gray Cary Ware & Friedenrich LLP, Suite 1600, 4365
Executive Drive, San Diego, CA 92121-2189, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200055302 A2 20000921 (WO 0055302)
Application: WO 2000US6915 20000316 (PCT/WO US0006915)
Priority Application: US 99124570 19990316; US 99170931 19991214; US
99172832 19991220

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK

DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK
LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL
TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 31214

English Abstract

The present invention provides cytochrome P450s useful for producing genetically modified plants characterized as having the phenotypic trait of modulated brassinolide synthesis of signaling, for example, resulting in insect resistance, dwarfism and darker-green foliage compared with wild type plants. Such plants can be modified, for example, using "bas1", or functional homologues thereof, a polypeptide encoded by bas1 that modulates brassinolide synthesis and/or signaling in plants. The invention also provides methods for modulating ecdysteroid activity in a plant and for assaying brassinosteroid function in a plant. The latter method can be used to create a gain-of-function allelic series of plants characterized by increasing levels of overexpression of a cytochrome P450 to screen for brassinolide activity in plant species.

French Abstract

La presente invention concerne des cytochromes P450 utilises dans la production de plantes genetiquement modifiees, caracterises en ce qu'ils presentent le trait phenotypique de la synthese ou de la signalisation brassinolide modifiee, par exemple, entrainant la resistance aux insectes, le nanisme et un feuillage vert plus fonce par rapport aux plantes de type sauvage. En l'occurrence, On peut modifier ces plantes, par exemple, a l'aide de " bas1 ", ou d'homologues fonctionnels de celles-ci, ou d'un polypeptide code par bas1 qui module la synthese et/ou la signalisation brassinolide chez les plantes. Par ailleurs, cette invention concerne des procedes de modulation de l'activite ecdysteroides et d'analyse de fonction brassinosteroide dans une plante. On peut utiliser ce dernier procede pour mettre au point une serie allele de plantes fonction de gain, caracterisees par des niveaux accrues de surexpression d'un cytochrome P450, dans le but d'analyser l'activite brassinolide dans une espece de plantes.

31/3,AB/12 (Item 3 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT
(c) 2002 WIPO/Univentio. All rts. reserv.

00571121

A RECOMBINANT VECTOR EXPRESSING MULTIPLE COSTIMULATORY MOLECULES AND USES THEREOF

VECTEUR RECOMBINE EXPRIMANT DES MOLECULES COSTIMULANTES MULTIPLES ET LEURS UTILISATIONS

Patent Applicant/Assignee:

THE GOVERNMENT OF THE UNITED STATES OF AMERICA represented by THE
SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES,
THERION BIOLOGICS CORPORATION,
SCHLOM Jeffrey,
HODGE James,
PANICALI Dennis,

Inventor(s):

SCHLOM Jeffrey,
HODGE James,
PANICALI Dennis,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200034494 A1 20000615 (WO 0034494)

Application: WO 99US26866 19991112 (PCT/WO US9926866)

Priority Application: US 98111582 19981209

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK

DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR

LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ

TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM

AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL

PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

Publication Language: English

Fulltext Word Count: 41813

English Abstract

The present invention is a recombinant vector encoding and expressing at least three or more costimulatory molecules. The recombinant vector may additionally contain a gene encoding one or more target antigens or immunological epitope thereof. The synergistic effect of these costimulatory molecules on the enhanced activation of T cells is demonstrated. The degree of T-cell activation using recombinant vectors containing genes encoding three costimulatory molecules was far greater than the sum of recombinant vector constructs containing one costimulatory molecule and greater than the use of two costimulatory molecules. Results employing the triple costimulatory vectors were most dramatic under conditions of either low levels of first signal or low stimulator to T-cell ratios. This phenomenon was observed with both isolated CD4+ and CD8+ T cells. The recombinant vectors of the present invention are useful as immunogenes and vaccines against cancer and pathogenic micro-organisms, and in providing host cells, including dendritic cells and splenocytes with enhanced %antigen%-presenting functions.

French Abstract

La presente invention est un vecteur recombiné codant et exprimant au moins trois molécules costimulantes ou davantage. Le vecteur recombiné peut également contenir un gène codant un ou plusieurs antigènes cibles ou leur épitope immunologique. L'effet synergique de ces molécules costimulantes sur l'activation renforcée des lymphocytes T est démontré. Le degré d'activation des lymphocytes T à l'aide de vecteurs recombinés contenant des gènes codant trois molécules costimulantes a été de loin supérieur à la somme des constructions de vecteurs recombinés contenant une molécule costimulante et supérieur à l'utilisation de deux molécules costimulantes. Les résultats employant les triples vecteurs costimulants se sont avérés spectaculaires dans des conditions de rapports entre soit de faibles niveaux d'un premier signal, soit un stimulateur faible et des lymphocytes T. On a observé ce phénomène avec des lymphocytes T isolés à la fois CD4+ et D8+. Les vecteurs recombinés de la présente invention sont utiles en tant qu'immunogènes et vaccins contre le cancer et des micro-organismes pathogènes, et pour obtenir des cellules hôtes, y compris des cellules dendritiques et des splénocytes présentant des fonctions renforcées de présentation d'antigène.

31/3,AB/13 (Item 4 from file: 349)

DIALOG(R) File 349:PCT FULLTEXT

(c) 2002 WIPO/Univentio. All rts. reserv.

00552286

STOMACH POLYPEPTIDE ZSIG28

POLYPEPTIDE STOMACHAL ZSIG28

Patent Applicant/Assignee:

ZYMOGENETICS INC,

Inventor(s):

SHEPPARD Paul O,

FOLEY Kevin P,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200015659 A2 20000323 (WO 0015659)

Application: WO 99US21023 19990914 (PCT/WO US9921023)

Priority Application: US 98154444 19980916

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE

ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT

LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT

UA UG UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD

RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF

CG CI CM GA GN GW ML MR NE SN TD TG

Publication Language: English

Fulltext Word Count: 31075

English Abstract

The present invention relates to polynucleotide and polypeptide molecules for zsig28, a novel member of the RPV.1 family of proteins. The polynucleotides encoding zsig28 can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.

French Abstract

La présente invention concerne des molécules de polynucleotides et de polypeptides de zsig28, nouveau membre de la famille RPV.1 des protéines. Les polynucleotides codant zsig28 peuvent servir à identifier une région du génome liée à des états pathologiques chez l'humain. La présente invention comprend également des procédés pour fabriquer la protéine, leur utilisation et des anticorps de ces molécules.

31/3,AB/14 (Item 5 from file: 349)

DIALOG(R) File 349:PCT FULLTEXT

(c) 2002 WIPO/Univentio. All rts. reserv.

00497988

AN OVER-EXPRESSING HOMOLOGOUS %ANTIGEN% VACCINE AND A METHOD OF MAKING THE

SAME

VACCIN CONTENANT UN ALLOANTIGENE SUREXPRIME ET SON PROCEDE DE PREPARATION

Patent Applicant/Assignee:

VIRGINIA TECH INTELLECTUAL PROPERTIES INC,
BOYLE Stephen M,
CRAVERO Silvio,
CORBEIL Lynette,
SCHURIG Gerhardt G,
SRIRNAGANATHAN Nammalwar,
VEMULAPALLI Ramesh,

Inventor(s):

BOYLE Stephen M,
CRAVERO Silvio,
CORBEIL Lynette,
SCHURIG Gerhardt G,
SRIRNAGANATHAN Nammalwar,
VEMULAPALLI Ramesh,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9929340 A1 19990617
Application: WO 97US23032 19971205 (PCT/WO US9723032)
Priority Application: WO 97US23032 19971205

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES

FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK
MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN
YU ZW GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK
ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN
TD TG

Publication Language: English

Fulltext Word Count: 5397

English Abstract

This invention relates to an over-expressing homologous %antigen% vaccine, a method of producing the same, and use of the vaccine for prophylaxis or treatment of vertebrates at risk of or suffering from disease caused by a pathogenic micro-organism. The vaccine is an attenuated or avirulent pathogenic micro-organism that %over%-expresses% at least one homologous %antigen% encoded by at least one gene derived from the pathogenic micro-organism, and may also express a heterologous %antigen%.

French Abstract

Cette invention concerne un vaccin contenant un alloantigene surexprime, un procede de preparation de ce vaccin et l'utilisation de ce dernier dans la prophylaxie ou le traitement de vertebres qui presentent le risque de souffrir d'une maladie provoquee par un micro-organisme pathogene ou qui souffrent deja d'une telle maladie. Le vaccin est un micro-organisme pathogene attenué ou avirulent qui surexprime au moins un alloantigene code par au moins un gene provenant du micro-organisme pathogene, et qui peut également exprimer un antigene heterologue.

31/3,AB/15 (Item 6 from file: 349)

DIALOG(R) File 349:PCT FULLTEXT

(c) 2002 WIPO/Univentio. All rts. reserv.

00412003

THERAPEUTIC MULTISPECIFIC COMPOUNDS COMPRISED OF ANTI-FC'alpha' RECEPTOR ANTIBODIES

COMPOSES THERAPEUTIQUES A SPECIFICITE MULTIPLE CONSISTANT EN ANTICORPS ANTI-RECEPTEURS DU FC'alpha'

Patent Applicant/Assignee:

MEDAREX INC,
DEO Yashwant M,
GRAZIANO Robert,
KELER Tibor,

Inventor(s):

DEO Yashwant M,
GRAZIANO Robert,
KELER Tibor,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9802463 A1 19980122

Application: WO 97US12013 19970710 (PCT/WO US9712013)

Priority Application: US 96678194 19960711

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CZ DE DK EE ES FI

GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW

MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI

FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

Publication Language: English

Fulltext Word Count: 27643

English Abstract

Multispecific compounds comprising at least one binding determinant which binds to the Fc γ -receptor on an effector cell. The other binding determinant(s) binds(s) to one or more antigens on a target cell, e.g., the Neu/Her-2 proto-oncogene product or the epidermal growth factor receptor on cancer cells, or to Candida antigens on infected cells. Examples are biospecific and trispecific antibodies. Therapeutic use of said multispecific compounds for treatment of cancers or pathogen infections.

French Abstract

L'invention porte sur des composés thérapeutiques à spécificité multiple comprenant au moins un déterminant de liaison se fixant aux récepteurs du FC γ d'une cellule effectrice. Les autres déterminants de liaison se fixent à un ou plusieurs antigènes d'une cellule cible, par exemple produit proto-oncogénique Neu/Her-2, récepteur du facteur de croissance épidermique de cellules cancéreuses ou aux antigènes du Candida de cellules infectées. Les exemples en sont des anticorps biospécifiques ou trispécifiques. L'invention porte également sur l'utilisation thérapeutique desdits composés multispécifiques pour le traitement du cancer et des infections dues à des pathogènes.

31/3,AB/16 (Item 7 from file: 349)

DIALOG(R) File 349:PCT FULLTEXT

(c) 2002 WIPO/Univentio. All rts. reserv.

00262149

CONJUGATE VACCINE AGAINST GROUP B STREPTOCOCCUS

VACCIN CONJUGUE CONTRE DES STREPTOCOQUES DU GROUPE B

Patent Applicant/Assignee:

THE GENERAL HOSPITAL CORPORATION,

BRIGHAM AND WOMEN'S HOSPITAL,

Inventor(s):

MICHEL James L,

KASPER Dennis L,

AUSUBEL Frederick M,

MADOFF Lawrence C,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9410317 A2 19940511

Application: WO 93US10506 19931102 (PCT/WO US9310506)

Priority Application: US 92968866 19921102

Designated States: AU CA FI HU JP KR NO NZ PL RU AT BE CH DE DK ES FR GB GR

IE IT LU MC NL PT SE

Publication Language: English

Fulltext Word Count: 28284

English Abstract

A vaccine capable of protecting a recipient from infection caused by group B Streptococcus. The vaccine provides polysaccharide-protein moieties and contain (a) a group B Streptococcus polysaccharide conjugated to (b) a functional derivative of a group B Streptococcus C protein alpha antigen that retains the ability to elicit protective antibodies against group B Streptococcus. The vaccine may contain only one type of such polysaccharide-protein unit or may contain a mixture of more than one type of unit.

French Abstract

On decrit un vaccin qui protege des infections dues a des streptocoques du groupe B. Ce vaccin presente des fractions polysaccharides-proteines et contient: a) un polysaccharide de streptocoque du groupe B conjugue a b) un derive fonctionnel d'un antigene alpha de proteine C d'un streptocoque du groupe B qui garde la capacite d'induire des anticorps protecteurs contre des streptocoques du groupe B. Ce vaccin peut ne contenir qu'un type d'une telle unite polysaccharide-proteine ou un melange de plusieurs types de ces unites.

31/3,AB/17 (Item 8 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT
(c) 2002 WIPO/Univentio. All rts. reserv.

00186706

CONJUGATE VACCINE FOR GROUP B STREPTOCOCCUS
VACCIN CONJUGUE POUR STREPTOCOQUE DU GROUPE B
Patent Applicant/Assignee:

THE GENERAL HOSPITAL CORPORATION,
BRIGHAM AND WOMEN'S HOSPITAL,

Inventor(s):

MICHEL James L,
KASPER Dennis L,
AUSUBEL Frederick M,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9104049 A1 19910404
Application: WO 90US5251 19900914 (PCT/WO US9005251)
Priority Application: US 8936 19890915

Designated States: AT AU BE CA CH DE DK ES FI FR GB HU IT JP KR LU NL NO SE
SU

Publication Language: English

Fulltext Word Count: 17268

English Abstract

A vaccine capable of protecting a recipient from infection caused by group B Streptococcus. The vaccine is formed by conjugating (a) a polysaccharide conjugated to (b) a protein; wherein both the polysaccharide and the protein are characteristic molecules of the group B Streptococcus.

French Abstract

L'invention concerne un vaccin pouvant proteger un receveur contre des infections provoquees par les streptocoques du groupe B. Le vaccin est forme par conjugaison (a) d'un polysaccharide conjugue avec (b) une proteine. Tant le polysaccharide que la proteine sont des molecules caracteristiques du streptocoque du groupe B.

31/3,AB/18 (Item 1 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS
(c) 2002 European Patent Office. All rts. reserv.

00452597

CONJUGATE VACCINE FOR GROUP B STREPTOCOCCUS
KONJUGATIMPFSTOFF FUR GRUPPE B-STREPTOCOCCUS
VACCIN CONJUGUE POUR STREPTOCOQUE DU GROUPE B
PATENT ASSIGNEE:

THE GENERAL HOSPITAL CORPORATION, (370400), 55 Fruit Street, Boston, MA
02114, (US), (applicant designated states:
AT;BE;CH;DE;DK;ES;FR;GB;IT;LI;LU;NL;SE)
BRIGHAM AND WOMEN'S HOSPITAL, (351461), 75 Francis Street, Boston,
Massachusetts 02115, (US), (applicant designated states:
AT;BE;CH;DE;DK;ES;FR;GB;IT;LI;LU;NL;SE)

INVENTOR:

MICHEL, James, L., 196 Winslow Road, Waban, MA 02168, (US)
KASPER, Dennis, L., 544 Ward Street, Newton Centre, MA 02159, (US)
AUSUBEL, Frederick, M., 271 Lake Avenue, Newton, MA 02161, (US)

LEGAL REPRESENTATIVE:

Aulmich, Gerhard, Dr. et al (241), Hoechst AG Patent- und
Lizenzabteilung Gebaude K 801, 65926 Frankfurt am Main, (DE)
PATENT (CC, No, Kind, Date): EP 491865 A1 920701 (Basic)
EP 491865 A1 930505
EP 491865 B1 961211
WO 9104049 910404
APPLICATION (CC, No, Date): EP 90915038 900914; WO 90US5251 900914
PRIORITY (CC, No, Date): US 408036 890915
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: A61K-039/09; C12N-015/31; C07K-016/46;
NOTE:

No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPAB96	366
CLAIMS B	(German)	EPAB96	382
CLAIMS B	(French)	EPAB96	363
SPEC B	(English)	EPAB96	14514
Total word count - document A			0
Total word count - document B			15625
Total word count - documents A + B			15625

31/3,AB/19 (Item 1 from file: 149)
DIALOG(R)File 149:TGG Health&Wellness DB(SM)
(c) 2002 The Gale Group. All rts. reserv.

01619731 SUPPLIER NUMBER: 18306605 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Cystic fibrosis in adults: from researcher to practitioner.
Marelích, Gregory P.; Cross, Carroll E.
The Western Journal of Medicine, v164, n4, p321(14)
April,
1996
PUBLICATION FORMAT: Magazine/Journal ISSN: 0093-0415 LANGUAGE: English
RECORD TYPE: Fulltext; Abstract TARGET AUDIENCE: Professional
WORD COUNT: 13175 LINE COUNT: 01133

AUTHOR ABSTRACT: The Cystic Fibrosis Foundation currently tracks about 20,000 Americans with cystic fibrosis, an autosomal recessive genetic disease that leads to multisystem complications. With the institution of better therapeutic regimens over the past 2 decades, more patients with this disease are surviving to adulthood. Within the past decade, both clinical and basic science research in the field of cystic fibrosis has progressed at a rapid rate. The intent of this review is to introduce readers to the molecular, cellular, and systemic disorders of this disease. We discuss treatment strategies involving antibiotics, nutrition, immune-response mediators, chest physiotherapy, and sputum-active agents with respect to the airway dysfunction of cystic fibrosis. Other common complications, recent developments, transplantation, and gene therapy are also reviewed.

31/3,AB/20 (Item 1 from file: 340)
DIALOG(R)File 340:CLAIMS(R)/US Patent
(c) 2002 IFI/CLAIMS(R). All rts. reserv.

Dialog Acc No: 3419951 IFI Acc No: 0038796
Document Type: C

OVER-EXPRESSING HOMOLOGOUS %ANTIGEN% VACCINE AND A METHOD OF MAKING THE SAME; VACCINE FOR IMMUNIZATION, PROPHYLAXIS OR TREATMENT OF A VERTEBRATE AT RISK OF OR SUFFERING FROM BRUCELLOSIS, WHEREIN SAID VACCINE COMPRISES AN ATTENUATED OR AVIRULENT STRAIN OF AN OTHERWISE %PATHOGENIC% %BACTERIA% OF THE GENUS BRUCELLA

Inventors: Boyle Stephen M (US); Corbeil Lynette (US); Cravero Silvio (AR); Schurig Gerhardt (US); Sriranganathan Nammalwar (US); Vemulapalli Ramesh (US)

Assignee: California, University of Regents; Virginia Tech Intellectual Properties Inc Assignee Code: 13234 21457

Publication (No,Date), Applic (No,Date)

US 6149920 20001121 US 9891521 19980619

Publication Kind: A

Calculated Expiration: 20171205

PCT Pub(No,Date),Applic(No,Date): WO 9929340 19990617 WO 97US23032
19971205

Section 371: 19980619

Section 102(e):19980619

Priority Applic(No,Date): US 9891521 19980619

Abstract:

This invention relates to an over-expressing homologous %antigen% vaccine, a method of producing the same, and use of the vaccine for prophylaxis or treatment of vertebrates at risk of or suffering from disease caused by a pathogenic micro-organism. The vaccine is an attenuated or avirulent pathogenic micro-organism that %over%-expresses% at least one homologous %antigen% encoded by at least one gene derived from the pathogenic micro-organism, and may also express a heterologous %antigen%.
? ds

Set	Items	Description
S1	8630	MULTICOPY (1W) PLASMID
S2	526502	S1 AND BACTERIA OR BACTERIUM
S3	2884	S2 AND S1
S4	325904	S3 AND OVER-EXPRESS? OR OVEREXPRESS?
S5	444	S4 AND S3
S6	280	S5 NOT PY>1997
S7	168	RD (unique items)
S8	357400	S7 AND VACCINE OR VACCINATION
S9	11	S8 AND S7
S10	11	RD (unique items)
S11	67	S7 AND HOMOLOGOUS
S12	67	RD (unique items)
S13	766274	S1 AND MYCOBACTERIUM OR TUBERCULOSIS OR BOVIS
S14	195	S13 AND S1
S15	325903	S14 AND OVER-EXPRESS? OR OVEREXPRESS?
S16	58	S15 AND S14
S17	43	RD (unique items)
S18	16609	BACTERIAL AND OVEREXPRESSION
S19	590398	S18 AND VACCINE OR IMMUNIZ?
S20	4532	S19 AND S18
S21	1036	S20 AND PATHOGEN
S22	781	S21 AND HOMOLOGOUS
S23	27772	S22 AND ATTENUATED OR AVIRULENT
S24	224	S23 AND S22
S25	9	S24 AND S1
S26	9	RD (unique items)
S27	63239	PATHOGENIC (1W) BACTERIA
S28	2720	S27 AND ANTIGEN
S29	3707	S28 AND OVER-EXPRESSES OR OVEREXPRESSES OR OVER (1W) EXPRE-
		SSES
S30	20	S29 AND S28
S31	20	RD (unique items)

Set	Items	Description
S1	8630	MULTICOPY (1W) PLASMID
S2	526502	S1 AND BACTERIA OR BACTERIUM
S3	2884	S2 AND S1
S4	325904	S3 AND OVER-EXPRESS? OR OVEREXPRESS?
S5	444	S4 AND S3
S6	280	S5 NOT PY>1997
S7	168	RD (unique items)

? t s7/3,ab/1-10

Set	Items	Description
S1	8630	MULTICOPY (1W) PLASMID
S2	526502	S1 AND BACTERIA OR BACTERIUM
S3	2884	S2 AND S1
S4	325904	S3 AND OVER-EXPRESS? OR OVEREXPRESS?
S5	444	S4 AND S3
S6	280	S5 NOT PY>1997
S7	168	RD (unique items)
S8	357400	S7 AND VACCINE OR VACCINATION
S9	11	S8 AND S7
S10	11	RD (unique items)
S11	67	S7 AND HOMOLOGOUS
S12	67	RD (unique items)
S13	766274	S1 AND MYCOBACTERIUM OR TUBERCULOSIS OR BOVIS
S14	195	S13 AND S1
S15	325903	S14 AND OVER-EXPRESS? OR OVEREXPRESS?
S16	58	S15 AND S14
S17	43	RD (unique items)
S18	16609	BACTERIAL AND OVEREXPRESSION
S19	590398	S18 AND VACCINE OR IMMUNIZ?
S20	4532	S19 AND S18
S21	1036	S20 AND PATHOGEN
S22	781	S21 AND HOMOLOGOUS
S23	27772	S22 AND ATTENUATED OR AVIRULENT
S24	224	S23 AND S22
S25	9	S24 AND S1
S26	9	RD (unique items)

? t s26/3,ab/1-9



>>>No matching display code(s) found in file(s): 135, 180, 342, 624, 765

26/3,AB/1 (Item 1 from file: 654)
 DIALOG(R)File 654:US PAT.FULL.
 (c) FORMAT ONLY 2002 THE DIALOG CORP. All rts. reserv.

03343425

Utility
 METHOD OF STIMULATING AN IMMUNE RESPONSE BY ADMINISTRATION OF HOST
 ORGANISMS THAT EXPRESS INTIMIN ALONE OR AS A FUSION PROTEIN WITH ONE OR
 MORE OTHER ANTIGENS

PATENT NO.: 6,261,561
 ISSUED: July 17, 2001 (20010717)
 INVENTOR(s): Stewart, Jr. C. Neal, Greensboro, NC (North Carolina), US
 (United States of America)
 McKee, Marian L., Great Falls, VA (Virginia), US (United
 States of America)
 O'Brien, Alison D., Bethesda, MD (Maryland), US (United States
 of America)
 Wachtel, Marian R., Albany, CA (California), US (United States
 of America)
 ASSIGNEE(s): Henry M Jackson Foundation for the Advancement of Military
 Medicine, (A U.S. Company or Corporation), Rockville, MD
 (Maryland), US (United States of America)
 APPL. NO.: 8-840,466
 FILED: April 18, 1997 (19970418)

CROSS-REFERENCE TO RELATED APPLICATION

This application is related to provisional applications entitled
 HISTIDINE-TAGGED INTIMIN AND METHODS OF USING INTIMIN TO STIMULATE AN
 IMMUNE RESPONSE AND AS AN ANTIGEN CARRIER WITH TARGETING CAPABILITY, of
 inventors Marian McKee, Alison O'Brien, and Marian Wachtel, Provisional
 Application No. 60-015,657, filed on Apr. 19, 1996, and Provisional
 Application No. 60-015,938, filed on Apr. 22, 1996; said applications are
 incorporated herein by reference.

GOVERNMENT INTEREST

The invention described herein may be manufactured, licensed and used for governmental purposes without the payment of any royalties to us thereon.

FULL TEXT: 2557 lines

ABSTRACT

This invention satisfies needs in the art by providing intimin, the Enterohemorrhagic Escherichia coli (EHEC) adherence protein, alone or as a fusion protein with one or more other antigens, expressed by transgenic plants and the use of those plants as vehicles for stimulating a protective immune response against EHEC and the one or more other antigens. Various plant species are transformed to protect various animal species and also humans against EHEC, against pathogens expressing intimin-like proteins, and against pathogens expressing any of the one or more other antigens to which intimin may be fused.

The eae gene encoding intimin, a functional portion thereof, or a recombination that encodes a fusion protein is put under the control of a constitutive plant promoter in a plasmid and the plasmid is introduced into plants by the type of transformation appropriate for the particular plant species. The engineered plants expressing intimin or the intimin fusion protein are then fed to animals and/or humans to elicit the production of antibodies, which protect the animals/humans against EHEC colonization and infection, and against pathogens expressing the one or more other antigens and any cross-reactive antigens. The invention may also be practiced by expressing the intimin or intimin fusion protein in other host organisms such as bacteria, yeast, and fungi.

26/3,AB/2 (Item 2 from file: 654)
DIALOG(R) File 654:US PAT.FULL.
(c) FORMAT ONLY 2002 THE DIALOG CORP. All rts. reserv.

03220360

Utility

OVER-EXPRESSING %HOMOLOGOUS% ANTIGEN %VACCINE% AND A METHOD OF MAKING THE SAME

[%Vaccine% for %immunization%, prophylaxis or treatment of a vertebrate at risk of or suffering from Brucellosis, wherein said %vaccine% comprises an %attenuated% or %avirulent% strain of an otherwise pathogenic bacteria of the genus Brucella]

PATENT NO.: 6,149,920

ISSUED: November 21, 2000 (20001121)

INVENTOR(s): Boyle, Stephen M., Blacksburg, VA (Virginia), US (United States of America)
Cravero, Silvio, Republica, AR (Argentina)
Corbeil, Lynette, San Diego, CA (California), US (United States of America)
Schurig, Gerhardt, Blacksburg, VA (Virginia), US (United States of America)
Srirnaganathan, Nammalwar, Blacksburg, VA (Virginia), US (United States of America)
Vemulapalli, Ramesh, Blacksburg, VA (Virginia), US (United States of America)

ASSIGNEE(s): The Regents of the University of California, (A U.S. Company or Corporation), La Jolla, CA (California), US (United States of America)
Virginia Tech Intellectual Properties, Inc, (A U.S. Company or Corporation), Blacksburg, VA (Virginia), US (United States of America)
[Assignee Code(s): 13234; 21457]

EXTRA INFO: Assignment transaction [Reassigned], recorded November 28, 2000 (20001128)
Assignment transaction [Reassigned], recorded November 30,

2000 (20001130)
APPL. NO.: 9-91,521
FILED: June 19, 1998 (19980619)
PCT: PCT-US97-23032 (WO 97US23032)
Section 371 Date: June 19, 1998 (19980619)
Section 102(e) Date: June 19, 1998 (19980619)
Filing Date: December 05, 1997 (19971205)
Publication Number: WO99-29340 (WO 9929340)
Publication Date: June 17, 1999 (19990617)

The invention described herein was made under a grant from the United States Department of Agriculture. Therefore, the U.S. government may have certain rights in this invention.

FULL TEXT: 520 lines

ABSTRACT

This invention relates to an over-expressing %homologous% antigen %vaccine% , a method of producing the same, and use of the %vaccine% for prophylaxis or treatment of vertebrates at risk of or suffering from disease caused by a pathogenic micro-organism. The %vaccine% is an %attenuated% or %avirulent% pathogenic micro-organism that over-expresses at least one %homologous% antigen encoded by at least one gene derived from the pathogenic micro-organism, and may also express a heterologous antigen.

26/3,AB/3 (Item 1 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT
(c) 2002 WIPO/Univentio. All rts. reserv.

00864262

WHOLE CELL ENGINEERING BY MUTAGENIZING A SUBSTANTIAL PORTION OF A STARTING GENOME, COMBINING MUTATIONS, AND OPTIONALLY REPEATING
INGENIERIE CELLULAIRE COMPLETE PAR MUTAGENESE D'UNE PARTIE SUBSTANTIELLE D'UN GENOME DE DEPART, PAR COMBINAISON DE MUTATIONS ET EVENTUELLEMENT REPETITION

Patent Applicant/Assignee:

DIVERSA CORPORATION, 4955 Directors Place, San Diego, CA 92121, US, US
(Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

SHORT Jay M, 6801 Paseo Delicias, P.O. Box 7214, Rancho Santa Fe, CA
92067-7214, US, US (Residence), US (Nationality), (Designated only for: US)

Legal Representative:

HAILE Lisa A (agent), Gray Cary Ware & Freidenrich LLP, Suite 1600, 4365
Executive Drive, San Diego, CA 92121-2189, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200196551 A2 20011220 (WO 0196551)
Application: WO 2001US19367 20010614 (PCT/WO US0119367)
Priority Application: US 2000594459 20000614; US 2000677584 20000930

Parent Application/Grant:

Related by Continuation to: US 2000594459 20000614 (CIP); US 2000677584
20000930 (CIP)

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD
SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 336587

English Abstract

An invention comprising cellular transformation, directed evolution, and

screening methods for creating novel transgenic organisms having desirable properties. Thus in one aspect, this invention relates to a method of generating a transgenic organism, such as a microbe or a plant, having a plurality of traits that are differentially activatable. Also, a method of retooling genes and gene pathways by the introduction of regulatory sequences, such as promoters, that are operable in an intended host, thus conferring operability to a novel gene pathway when it is introduced into an intended host. For example a novel man-made gene pathway, generated based on microbially-derived progenitor templates, that is operable in a plant cell. Furthermore, a method of generating novel host organisms having increased expression of desirable traits, recombinant genes, and gene products.

French Abstract

L'invention porte sur des procedes de transformation cellulaire, d'evolution dirigee et de criblage en vue de creer de nouveaux organismes transgeniques aux proprietes souhaitees. En variante, cette invention porte sur un procede de generation d'un organisme transgenique tel qu'un microbe ou une plante presentant une pluralite de caracteristiques pouvant etre activees de maniere differentielle. L'invention porte aussi sur un procede permettant de restructurer des genes et des mecanismes d'action genetiques par l'introduction de sequences regulatrices telles que des promoteurs pouvant agir dans un hote determine, ce qui confere une operabilite a un nouveau mecanisme d'action genetique lorsqu'il est introduit dans un hote determine. Par exemple, un nouveau mecanisme d'action genetique artificiel, genere a partir de gabarits de progeniteurs derives de microbes, peut etre utilise dans une cellule vegetale. L'invention porte en outre sur de nouveaux organismes hotes dont les caracteristiques souhaitees, les genes de recombinaison et les produits geniques ont une expression accrue.

26/3,AB/4 (Item 2 from file: 349)

DIALOG(R) File 349:PCT FULLTEXT

(c) 2002 WIPO/Univentio. All rts. reserv.

00827566

GENE DISRUPTION METHODOLOGIES FOR DRUG TARGET DISCOVERY

METHODOLOGIES DE DISRUPTION GENIQUE DESTINEES A LA DECOUVERTE DE MEDICAMENTS CIBLES

Patent Applicant/Assignee:

ELITRA PHARMACEUTICALS INC, Suite A, 3510 Dunhill Street, San Diego, CA 92121, US, US (Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

ROEMER Terry, 4935 Connaught Avenue, Montreal, Quebec H4V 1X4, CA, CA (Residence), CA (Nationality), (Designated only for: US)

JIANG Bo, 5231 Globert Street, Montreal, Quebec H3W 2E6, CA, CA (Residence), CA (Nationality), (Designated only for: US)

BOONE Charles, 254 Glenrose Avenue, Toronto, Ontario M4T 1K9, CA, CA (Residence), CA (Nationality), (Designated only for: US)

BUSSEY Howard, 325 Victoria Avenue, Westmount, Quebec H3Z 2N1, CA, CA (Residence), CA (Nationality), (Designated only for: US)

Legal Representative:

CORUZZI Laura A (et al) (agent), Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200160975 A2 20010823 (WO 0160975)

Application: WO 2001US5551 20010220 (PCT/WO US0105551)

Priority Application: US 2000183534 20000218

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ

DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ

LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG

SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

English Abstract

The present invention provides methods and compositions that enable the experimental determination as to whether any gene in the genome of a diploid pathogenic organism is essential, and whether it is required for virulence or pathogenicity. The methods involve the construction of genetic mutants in which one allele of a specific gene is inactivated while the other allele of the gene is placed under conditional expression. The identification of essential genes and those genes critical to the development of virulent infections, provides a basis for the development of screens for new drugs against such pathogenic organisms. The present invention further provides *Candida albicans* genes that are demonstrated to be essential and are potential targets for drug screening. The nucleotide sequence of the target genes can be used for various drug discovery purposes, such as expression of the recombinant protein, hybridization assay and construction of nucleic acid arrays. The uses of proteins encoded by the essential genes, and genetically engineered cells comprising modified alleles of essential genes in various screening methods are also encompassed by the invention.

French Abstract

L'invention concerne des procedes et compositions permettant de determiner de maniere experimentale si un quelconque gene du genome d'un organisme pathogene diploide est essentiel et s'il est necessaire a la virulence ou au pouvoir pathogene. Ces procedes consistent a construire des mutants genetiques dans lesquels un allele d'un gene specifique est inactive tandis que l'autre allele du gene est place dans des conditions d'eventuelle expression. L'identification de genes essentiels et de genes critiques quant au developpement d'infections virulentes constitue une base de developpement du criblage de nouveaux medicaments diriges contre ces organismes pathogenes. L'invention concerne encore des genes *Candida albicans* qui se sont reveles etre essentiels dans le criblage de medicaments et constituent des cibles potentielles a cette fin. On peut utiliser la sequence nucleotidique de ces genes cibles a des fins de decouverte de medicaments, telle que l'expression de la proteine de recombinaison, le dosage d'hybridation et la construction d'ensembles d'acides nucleiques. L'invention concerne enfin l'utilisation de proteines, codees par les genes essentiels, et de cellules modifiees genetiquement et comprenant des alleles modifiees de genes essentiels, dans divers procedes de criblage.

26/3,AB/5 (Item 3 from file: 349)
DIALOG(R) File 349:PCT FULLTEXT
(c) 2002 WIPO/Univentio. All rts. reserv.

00568674

PLASMID MAINTENANCE SYSTEM FOR ANTIGEN DELIVERY
SYSTEME DE STABILISATION DE PLASMIDES PERMETTANT D'ADMINISTRER DES
ANTIGENES

Patent Applicant/Assignee:

UNIVERSITY OF MARYLAND BALTIMORE,
GALEN James E,

Inventor(s):

GALEN James E,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200032047 A1 20000608 (WO 0032047)

Application: WO 99US28499 19991202 (PCT/WO US9928499)

Priority Application: US 98204117 19981202; US 99158738 19991012

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE

ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT

LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT

UA UG US VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ

MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ

CF CG CI CM GA GN GW ML MR NE SN TD TG

Publication Language: English

Fulltext Word Count: 34866

English Abstract

The present invention relates generally to a Plasmid Maintenance System for the stabilization of expression plasmids encoding foreign antigens, and methods for making and using the Plasmid Maintenance System. The invention optimizes the maintenance of expression plasmids at two independent levels by: (1) removing sole dependence on balanced lethal maintenance functions; and (2) incorporating at least one plasmid partition function to prevent random segregation of expression plasmids, thereby enhancing their inheritance and stability. The Plasmid Maintenance System may be employed within a plasmid which has been recombinantly engineered to express a variety of expression products.

French Abstract

L'invention concerne en general un systeme de stabilisation de plasmides, permettant de stabiliser des plasmides d'expression qui codent pour des antigenes etrangers, et des procedes de production et d'utilisation dudit systeme de stabilisation de plasmides. L'invention optimise la stabilisation de plasmides a deux niveaux independants: 1) par elimination d'une dependance exclusive sur des fonctions de stabilisation letale equilibrees; et 2) par incorporation d'au moins une fonction de partition de plasmide, afin d'empêcher la segregation aleatoire des plasmides d'expression, ce qui ameliore leur heredite et leur stabilite. Le systeme de stabilisation de plasmides peut etre utilise dans un plasmide qui a ete mis au point par genie genetique par recombinaison, afin d'exprimer une variete de produits d'expression.

26/3,AB/6 (Item 4 from file: 349)

DIALOG(R) File 349:PCT FULLTEXT

(c) 2002 WIPO/Univentio. All rts. reserv.

00542044

METHODS AND COMPOSITIONS FOR THE DETERMINATION OF PROTEIN FUNCTION AND IDENTIFICATION OF MODULATORS THEREOF

METHODES ET COMPOSITIONS POUR DETERMINER UNE FONCTION PROTEIQUE ET IDENTIFIER LES MODULATEURS DE CELLE-CI

Patent Applicant/Assignee:

SMALL MOLECULE THERAPEUTICS INC,

Inventor(s):

MENZEL Rolf,

KHAZAK Vladimir,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200005417 A1 20000203 (WO 0005417)

Application: WO 99US16749 19990723 (PCT/WO US9916749)

Priority Application: US 9893855 19980723

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE

ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT

LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT

UA UG UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU

TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

CI CM GA GN GW ML MR NE SN TD TG

Publication Language: English

Fulltext Word Count: 31503

English Abstract

The present invention provides libraries of tag dominant-negative elements (TDNE) and methods enabling the identification of specific TDNEs that act as dominant-negative elements on a target protein of interest. The present invention further relates to the use of such TDNEs and dominant-negative elements for the identification of protein-protein interactions, and the determination of a target protein's biological activity and function. Furthermore, the present invention relates to the development of means, including small molecule compounds, for disrupting the target protein's biological function and activity.

French Abstract

La presente invention concerne des banques d'elements marqueurs negatifs dominants (TDNE), ainsi que des methodes permettant d'identifier des

elements TDNE spécifiques agissant comme des éléments négatifs dominants sur une protéine cible recherchée. La présente invention concerne également l'utilisation de ces éléments TDNE, et de ces éléments négatifs dominants, pour identifier des interactions protéine-protéine, et pour déterminer l'activité et la fonction biologiques de la protéine cible. La présente invention concerne enfin le développement de moyens, notamment de composés de petites molécules, permettant de rompre l'activité et la fonction biologiques de ladite protéine cible.

26/3,AB/7 (Item 5 from file: 349)
DIALOG(R) File 349:PCT FULLTEXT
(c) 2002 WIPO/Univentio. All rts. reserv.

00399434

METHOD OF STIMULATING AN IMMUNE RESPONSE BY ADMINISTRATION OF HOST ORGANISMS THAT EXPRESS INTIMIN ALONE OR AS A FUSION PROTEIN WITH ONE OR MORE OTHER ANTIGENS

PROCEDE DE STIMULATION D'UNE REACTION IMMUNITAIRE PAR ADMINISTRATION D'ORGANISMES HOTES QUI EXPRIMENT L'INTIMINE SEULE OU SOUS FORME DE PROTEINE DE FUSION ASSOCIEE A UN OU PLUSIEURS ANTIGENES

Patent Applicant/Assignee:

HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE,

Inventor(s):

STEWART Charles N,
MCKEE Marian L,
O'BRIEN Alison D,
WACHTEL Marian R,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9740177 A1 19971030

Application: WO 97US5831 19970418 (PCT/WO US9705831)

Priority Application: US 9615657 19960419; US 9615938 19960422

Designated States: AU CA JP AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

Publication Language: English

Fulltext Word Count: 26054

English Abstract

This invention satisfies needs in the art by providing intimin, the Enterohemorrhagic Escherichia coli (EHEC) adherence protein, alone or as a fusion protein with one or more other antigens, expressed by transgenic plants and the use of those plants as vehicles for stimulating a protective immune response against EHEC and the one or more other antigens. Various plant species are transformed to protect various animal species and also humans against EHEC, against pathogens expressing intimin-like proteins, and against pathogens expressing any of the one or more other antigens to which intimin may be fused. The eae gene encoding intimin, a functional portion thereof, or a recombination that encodes a fusion protein is put under the control of a constitutive plant promoter in a plasmid and the plasmid is introduced into plants by the type of transformation appropriate for the particular plant species. The engineered plants expressing intimin or the intimin fusion protein are then fed to animals and/or humans to elicit the production of antibodies, which protect the animals/humans against EHEC colonization and infection, and against pathogens expressing the one or more other antigens and any cross-reactive antigens. The invention may also be practiced by expressing the intimin or intimin fusion protein in other host organisms such as bacteria, yeast, and fungi.

French Abstract

Cette invention se rapporte à l'administration d'intimine, la protéine d'adhérence à Escherichia coli entérohémorragique (EHEC), seule ou sous forme de protéine de fusion associée à un ou plusieurs antigènes, exprimée par des plantes transgéniques et à l'utilisation de ces plantes comme véhicules permettant de stimuler une réaction immunitaire protectrice dirigée contre EHEC et le ou les autres antigènes. Diverses espèces végétales sont transformées pour protéger diverses espèces animales et également les êtres humains contre EHEC, contre des pathogènes exprimant des protéines de type intimine, et contre des

organismes pathogenes exprimant l'un quelconque des antigenes a
lesquels l'intimine peut fusionner. On met le gene eae codant l'intimine,
une fraction fonctionnelle de ce gene, ou un produit de recombinaison qui
code une proteine de fusion sous le controle d'un promoteur vegetal
constitutif dans un plasmide et l'on introduit ledit plasmide dans des
plantes par le biais d'une transformation adaptee aux especes vegetales
en question. On introduit ensuite les plantes manipulees genetiquement
qui expriment l'intimine ou la proteine de fusion avec l'intimine, dans
des animaux et/ou des humains pour susciter la production d'anticorps,
qui protegent ces animaux ou humains contre une colonisation de EHEC et
une infection, et contre des organismes pathogenes exprimant un ou
plusieurs antigenes et tous les antigenes a reaction croisee. Le procede
de l'invention peut etre mis en oeuvre par expression de l'intimine ou de
la proteine de fusion avec l'intimine dans d'autres organismes hotes du
type bacteries, levures et champignons.

26/3,AB/8 (Item 6 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT
(c) 2002 WIPO/Univentio. All rts. reserv.

00383708

EPISOMAL VECTOR AND USES THEREOF
VECTEUR EPISOMIQUE ET SON UTILISATION

Patent Applicant/Assignee:

ESTONIAN BIOCENTRE,

USTAV Mart,

Inventor(s):

USTAV Mart,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9724451 A2 19970710

Application: WO 96EE4 19961227 (PCT/WO EE9600004)

Priority Application: US 958581269 19951229

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES

FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW

MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN KE LS MW

SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT

LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

Publication Language: English

Fulltext Word Count: 25393

English Abstract

The invention relates to a recombinant vector for stable persistence of
erogenous DNA in a eukaryotic host cell, and the uses of the recombinant
vector for long-term stable production of a gene product in the host
cell, the vector including the minimal origin of replication of
papillomavirus and the minichromosomal maintenance element of
papillomavirus.

French Abstract

L'invention a trait a un vecteur de recombinaison aux fins d'une
remanence stable d'un ADN erogene dans une cellule hote eucaryote ainsi
qu'a l'utilisation qui en est faite pour produire a long terme et de
facon stable un produit genique dans la cellule hote, ce vecteur
comprenant le principe minimal de replication d'un papillomavirus et
l'element minichromosomique de remanence du virus.

26/3,AB/9 (Item 1 from file: 211)
DIALOG(R)File 211:Gale Group Newsearch(TM)
(c) 2002 The Gale Group. All rts. reserv.

14112688 Supplier Number: 82535394 (Use format 7 or 9 for FULL TEXT)

Free radicals in the physiological control of cell function.

Droge, Wulf

Physiological Reviews, 82, 1, 47(50)

Jan, 2002

ISSN: 0031-9333

LANGUAGE: English

RECORD TYPE: Fulltext

WORD COUNT: 45045

LINE COUNT: 03705